185 related articles for article (PubMed ID: 28281325)
21. Irp2 Knockout Causes Osteoporosis by Inhibition of Bone Remodeling.
Zhou Y; Yang Y; Liu Y; Chang H; Liu K; Zhang X; Chang Y
Calcif Tissue Int; 2019 Jan; 104(1):70-78. PubMed ID: 30191282
[TBL] [Abstract][Full Text] [Related]
22. BRAF V600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells.
Sueda T; Sakai D; Kawamoto K; Konno M; Nishida N; Koseki J; Colvin H; Takahashi H; Haraguchi N; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Satoh T; Doki Y; Mori M; Ishii H
Sci Rep; 2016 Jan; 6():18949. PubMed ID: 26750638
[TBL] [Abstract][Full Text] [Related]
23. Mdm2 is a target and mediator of IRP2 in cell growth control.
Zhang J; Kong X; Zhang Y; Sun W; Xu E; Chen X
FASEB J; 2020 Feb; 34(2):2301-2311. PubMed ID: 31907996
[TBL] [Abstract][Full Text] [Related]
24. Perturbation of Iron Metabolism by Cisplatin through Inhibition of Iron Regulatory Protein 2.
Miyazawa M; Bogdan AR; Tsuji Y
Cell Chem Biol; 2019 Jan; 26(1):85-97.e4. PubMed ID: 30449675
[TBL] [Abstract][Full Text] [Related]
25. BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells.
Goulielmaki M; Koustas E; Moysidou E; Vlassi M; Sasazuki T; Shirasawa S; Zografos G; Oikonomou E; Pintzas A
Oncotarget; 2016 Feb; 7(8):9188-221. PubMed ID: 26802026
[TBL] [Abstract][Full Text] [Related]
26. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
[TBL] [Abstract][Full Text] [Related]
27. Circadian Clock in a Mouse Colon Tumor Regulates Intracellular Iron Levels to Promote Tumor Progression.
Okazaki F; Matsunaga N; Okazaki H; Azuma H; Hamamura K; Tsuruta A; Tsurudome Y; Ogino T; Hara Y; Suzuki T; Hyodo K; Ishihara H; Kikuchi H; To H; Aramaki H; Koyanagi S; Ohdo S
J Biol Chem; 2016 Mar; 291(13):7017-28. PubMed ID: 26797126
[TBL] [Abstract][Full Text] [Related]
28. Iron Regulatory Protein 2 Exerts its Oncogenic Activities by Suppressing TAp63 Expression.
Zhang Y; Feng X; Zhang J; Chen X
Mol Cancer Res; 2020 Jul; 18(7):1039-1049. PubMed ID: 32276991
[TBL] [Abstract][Full Text] [Related]
29. Iron regulatory protein-2 knockout increases perihematomal ferritin expression and cell viability after intracerebral hemorrhage.
Chen M; Awe OO; Chen-Roetling J; Regan RF
Brain Res; 2010 Jun; 1337():95-103. PubMed ID: 20399759
[TBL] [Abstract][Full Text] [Related]
30. Iron regulatory protein 2 is a suppressor of mutant p53 in tumorigenesis.
Zhang Y; Feng X; Zhang J; Chen M; Huang E; Chen X
Oncogene; 2019 Aug; 38(35):6256-6269. PubMed ID: 31332290
[TBL] [Abstract][Full Text] [Related]
31. Tumorigenic properties of iron regulatory protein 2 (IRP2) mediated by its specific 73-amino acids insert.
Maffettone C; Chen G; Drozdov I; Ouzounis C; Pantopoulos K
PLoS One; 2010 Apr; 5(4):e10163. PubMed ID: 20405006
[TBL] [Abstract][Full Text] [Related]
32. BRAF
Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
[TBL] [Abstract][Full Text] [Related]
33. Altered iron metabolism, transferrin receptor 1 and ferritin in patients with colon cancer.
Prutki M; Poljak-Blazi M; Jakopovic M; Tomas D; Stipancic I; Zarkovic N
Cancer Lett; 2006 Jul; 238(2):188-96. PubMed ID: 16111806
[TBL] [Abstract][Full Text] [Related]
34. β-catenin-IRP2-primed iron availability to mitochondrial metabolism is druggable for active β-catenin-mediated cancer.
Wu Y; Yang S; Han L; Shang K; Zhang B; Gai X; Deng W; Liu F; Zhang H
J Transl Med; 2023 Jan; 21(1):50. PubMed ID: 36703130
[TBL] [Abstract][Full Text] [Related]
35. Hyperinsulinemia induces hepatic iron overload by increasing liver TFR1 via the PI3K/IRP2 pathway.
Jiang X; Wang H; Shi W; Shen Z; Shen H; Li M
J Mol Endocrinol; 2014 Dec; 53(3):381-92. PubMed ID: 25385842
[TBL] [Abstract][Full Text] [Related]
36. Transferrin receptor regulates malignancies and the stemness of hepatocellular carcinoma-derived cancer stem-like cells by affecting iron accumulation.
Xiao C; Fu X; Wang Y; Liu H; Jiang Y; Zhao Z; You F
PLoS One; 2020; 15(12):e0243812. PubMed ID: 33351833
[TBL] [Abstract][Full Text] [Related]
37. The role of endogenous heme synthesis and degradation domain cysteines in cellular iron-dependent degradation of IRP2.
Bourdon E; Kang DK; Ghosh MC; Drake SK; Wey J; Levine RL; Rouault TA
Blood Cells Mol Dis; 2003; 31(2):247-55. PubMed ID: 12972033
[TBL] [Abstract][Full Text] [Related]
38. Iron metabolism and the IRE/IRP regulatory system: an update.
Pantopoulos K
Ann N Y Acad Sci; 2004 Mar; 1012():1-13. PubMed ID: 15105251
[TBL] [Abstract][Full Text] [Related]
39. Severity of neurodegeneration correlates with compromise of iron metabolism in mice with iron regulatory protein deficiencies.
Smith SR; Cooperman S; Lavaute T; Tresser N; Ghosh M; Meyron-Holtz E; Land W; Ollivierre H; Jortner B; Switzer R; Messing A; Rouault TA
Ann N Y Acad Sci; 2004 Mar; 1012():65-83. PubMed ID: 15105256
[TBL] [Abstract][Full Text] [Related]
40. Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer.
Seo Y; Ishii Y; Ochiai H; Fukuda K; Akimoto S; Hayashida T; Okabayashi K; Tsuruta M; Hasegawa H; Kitagawa Y
Oncol Rep; 2014 May; 31(5):2115-22. PubMed ID: 24626880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
